
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is a leading life science technology company with a diverse product portfolio, including its Chromium platform for studying biological components. The company has a strong financial position, with expected after-tax NPV5% of US$1,491M and IRR of 37.3%, and plans for sustainable growth through internally funded development projects. Its solid track record of shareholder returns, including repurchasing 3.2% of shares in 2025 and a planned US$350M return in 2026, demonstrates the company's commitment to driving value for investors.
Bears say
10x Genomics is facing challenges as their Q2 production and sales figures fell below expectations due to lower-grade and lower-gold-recovery areas in the Media Luna project. This resulted in YTD output falling within the lower half of the company's guidance and highlights the need for improved grades in the second half of the year. While the company's plans for the Media Luna North project may help in grade improvement, it may not be enough to significantly improve the company's financial performance.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares